ACN vs ZVRA · P/E 24, rev $17.60B vs P/E 6.3, rev $75.9M
Accenture plc (ACN) versus Zevra Therapeutics Inc. (ZVRA) — a side-by-side from cached financials, not a winner call.
Accenture plc (ACN) is a information technology services company listed on US.
Zevra Therapeutics Inc. (ZVRA) is a biotechnology company listed on NASDAQ.
Latest reported ACN revenue for 2025-08-31 was $17.60B. Net income was $1.41B. Revenue was down 0.7% from 2025-05-31 to 2025-08-31. ACN currently screens at market cap $186.16B and trailing P/E 23.8.
Latest reported ZVRA revenue for 2026-06-30 was $75.9M. Net income was $46.6M. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
ACN currently screens at market cap $186.16B and trailing P/E 23.8. ZVRA currently screens at market cap $745.4M and trailing P/E 6.3.
Not investment advice. Open the ACN and ZVRA stock pages for the full models.
Not investment advice.